Join us for our third live panel discussion highlighting the challenges and anticipated effects on drug development during the COVID-19 pandemic. During this 1-hour session:
- Hear directly from sponsors about the impact of the pandemic on their development programs
- Learn about obstacles faced by many sponsors when developing treatments for diseases outside of COVID-19
- Discuss trends our consultants are seeing in development from various clients
Meet the Panelists
Paul L. Feldman, Ph.D.
Head of Discovery and Translational Medicine, Intarcia Therapeutics
Dr. Feldman joined Intarcia in September 2015 as Head of Discovery and Translational Medicine following Intarcia’s acquisition of Phoundry Pharmaceuticals, Inc., a peptide therapeutic discovery company, where he was a co-founder and CEO. Dr. Feldman’s accomplishments include: contributing to the discovery and development of multiple medicines, leading national and international multi-disciplinary discovery and early development groups, plus much more.
Ronda Rippley, Ph.D.
Vice President, Head of Clinical Pharmacology, Boston Pharmaceuticals
Dr. Rippley has 20+ years of business and scientific contributions impacting drug development. She has served as a scientist, supervisor, manager and area leader within clinical PK/PD and Quantitative Pharmacology organizations at multiple companies including Regeneron, Merck and Amgen. In recent years, she has expanded into the discovery/translational and market/payer spaces.
Todd Shearer, Ph.D.
Senior Director, Clinical Pharmacology, SpringWorks Therapeutics
Dr. Shearer has 18+ years working in drug discovery, preclinical and clinical development across a diverse set of therapeutic areas. His principal areas of expertise include pharmacokinetics, bioanalysis, pharmacology, large and small molecules DMPK, drug discovery, and clinical pharmacology. He currently serves as Senior Director of Clinical Pharmacology at SpringWorks Therapeutics, a clinical-stage biopharmaceutical company that pioneers efficient pathways for drug development for patients with severe rare diseases and cancer.
Meet the Moderator
Devin Welty, Ph.D.
Senior Consultant, Nonclinical & Clinical Pharmacology, Nuventra
Dr. Welty has over 25 years of experience in preclinical and clinical pharmacology leading organizations and projects teams from early discovery to approval and commercialization, most recently as the Global Head of DMPK, Shire. He has extensive experience in pharmacokinetics, pharmacodynamics and systems pharmacology and adopting model-informed approaches for candidate nomination and efficient clinical development strategy.